Nat Med. 2005 Jun;11(6):615-22. Epub 2005 May 8.

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF.

Source

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland. alexandra.trkola@usz.ch

Abstract

To determine the protective potential of the humoral immune response against HIV-1 in vivo we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in suppressing viral rebound in six acutely and eight chronically HIV-1-infected individuals undergoing interruption of antiretroviral treatment (ART). Only two of eight chronically infected individuals showed evidence of a delay in viral rebound during the passive immunization. Rebound in antibody-treated acutely infected individuals upon cessation of ART was substantially later than in a control group of 12 individuals with acute infection. Escape mutant analysis showed that the activity of 2G12 was crucial for the in vivo effect of the neutralizing antibody cocktail. By providing further direct evidence of the potency, breadth and titers of neutralizing antibodies that are required for in vivo activity, these data underline both the potential and the limits of humoral immunity in controlling HIV-1 infection.

Comment in

Nat Med. 2005 Jun;11(6):593-4.

PMID:: 15880120; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Related citations

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. [AIDS. 2002]
Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation.
Stiegler G, Armbruster C, Vcelar B, Stoiber H, Kunert R, Michael NL, Jagodzinski LL, Ammann C, Jäger W, Jacobson J, et al. AIDS. 2002 Oct 18; 16(15):2019-25.
Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). [Antimicrob Agents Chemother. 2006]
Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, Armbruster C, Vcelar B, Katinger H, Günthard HF. Antimicrob Agents Chemother. 2006 May; 50(5):1773-9.
Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. [J Virol. 2007]
Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection.
Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, Boden D, Galovich J, Tenner-Racz K, Racz P, et al. J Virol. 2007 Oct; 81(20):11016-31. Epub 2007 Aug 8.
Review Passive immunization for the treatment of HIV infection. [Mt Sinai J Med. 1998]
Review Passive immunization for the treatment of HIV infection.
Jacobson JM. Mt Sinai J Med. 1998 Jan; 65(1):22-6.
Review Defining the protective antibody response for HIV-1. [Curr Mol Med. 2003]
Review Defining the protective antibody response for HIV-1.
Mascola JR. Curr Mol Med. 2003 May; 3(3):209-16.

See reviews... See all...

Cited by 75 PubMed Central articles

Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. [PLoS One. 2011]
Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.
Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TY, Velinzon K, Seaman MS, Nussenzweig MC. PLoS One. 2011; 6(9):e24078. Epub 2011 Sep 8.
Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. [PLoS One. 2011]
Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.
Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, et al. PLoS One. 2011 Apr 1; 6(4):e17665. Epub 2011 Apr 1.
MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. [J Exp Med. 2011]
MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1.
Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, Abela IA, Regoes RR, Günthard HF, Rusert P, et al. J Exp Med. 2011 Mar 14; 208(3):439-54. Epub 2011 Feb 28.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive...
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
Nat Med. 2005 Jun ;11(6):615-22. Epub 2005 May 8 .

PubMed
Presence of secretory leukocyte protease inhibitor in human endometrium and firs...
Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role.
Mol Hum Reprod. 2000 Feb ;6(2):191-6.

PubMed
Pleasant music overcomes the loss of awareness in patients with visual neglect.
Pleasant music overcomes the loss of awareness in patients with visual neglect.
Proc Natl Acad Sci U S A. 2009 Apr 7 ;106(14):6011-6. Epub 2009 Mar 23 .

PubMed
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized...
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
AIDS. 2001 Sep 28 ;15(14):1811-22.

PubMed
Lack of efficacy of finasteride in postmenopausal women with androgenetic alopec...
Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
J Am Acad Dermatol. 2000 Nov ;43(5 Pt 1):768-76.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Source

Abstract

Comment in

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Related citations

Cited by 75 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information